Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective.
J Comp Eff Res
; 12(2): e220089, 2023 02.
Article
em En
| MEDLINE
| ID: mdl-36655745
ABSTRACT
Aim:
The cost-effectiveness of treatment options (anticholinergics, ß3-adrenoceptor agonists, onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were compared with best supportive care (BSC) using a previously published Markov model. Materials &methods:
Cost-effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were derived from published sources.Results:
Using Medicare and commercial costs over a 15-year time period, onabotulinumtoxinA 100U had incremental cost-effectiveness ratios (ICERs) gained of $39,591/quality-adjusted life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA to be the most cost-effective of all assessed treatments versus BSC.Conclusion:
OnabotulinumtoxinA 100U is currently the most cost-effective treatment for OAB.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Toxinas Botulínicas Tipo A
/
Bexiga Urinária Hiperativa
Tipo de estudo:
Health_economic_evaluation
Limite:
Aged
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Comp Eff Res
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos